Close Menu

NEW YORK (GenomeWeb) – DermTech announced today that it has raised $10 million of its Series C preferred equity offering.

"We are very pleased to have the investor support allowing us to reach $10 million in preferred stock sold out of our $15 million offering," DermTech CFO Steve Kemper said in a statement.

The company said it would use the proceeds of the offering to continue the expansion of its sales force and bring new skin cancer products to market in 2018.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Apr
29
Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May
13
Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

May
18
Sponsored by
Bio-Rad

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.